Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug…
- Trial name
- NCT00421122
- Testing
- budesonide/formoterol (Symbicort), budesonide (Pulmicort), terbutaline sulfate (Bricasol)
- Where
- 8 sites in China
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled study. Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of either FDC (fixed-dose combination) of…
- Trial name
- NCT02683109
- Testing
- FDC of tiotropium + olodaterol, Tiotropium, Olodaterol
- Where
- 22 sites in Austria, Denmark and 3 more
- Volunteers
- 221 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
The purpose of this study is to evaluate the safety and efficacy of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema refractory to medical therapy.
- Trial name
- NCT00517998
- Testing
- Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease
A40 Expiratory Flow Limitation Registry
This prospective observational multicenter registry study will include adults greater than 40 years old, diagnosed with chronic obstructive pulmonary disease, requiring home noninvasive ventilation as part of standard medical…
- Trial name
- NCT04419428
- Testing
- BiPAP A40 Expiratory Flow Limitation (EFL)
- Where
- United Kingdom
- Sponsor
- Philips Clinical & Medical Affairs Global
Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF)
Clinical Trials for Elderly Patients With Multiple Disease
The CHROMED project focuses its investigation on the applicability of an integrated solution for a pathological condition which: a) is very prevalent in ageing patients and b) severely impairs quality of life: COPD with other…
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Sleep Disordered Breathing (SDB)
- Trial name
- CHROMED (NCT01960907)
- Testing
- CHROMED monitoring system
- Where
- 6 sites in Estonia, Slovenia and 3 more
- Volunteers
- 312 people
- Sponsor
- Restech Srl
COPD, Chronic Obstructive Pulmonary Disease
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
- Trial name
- NCT00215423
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dey
COPD, Chronic Obstructive Pulmonary Disease
Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD
The clinical objectives of this study are to determine whether utilization of the Wellinks COPD Solution can improve quality of life for patients with COPD, can reduce healthcare resource utilization over time, and can improve…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
- Trial name
- ASPIRE (NCT05259280)
- Testing
- Wellinks
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- Convexity Scientific Inc
Pulmonary Disease, Chronic Obstructive
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones.
- Trial name
- NCT00355342
- Testing
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Where
- 37 sites in United States
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
- Trial name
- NCT01192191
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
- Where
- 35 sites in Japan
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Compliance, Patient
AdHerencE to Treatment and quAlity of Life in COPD
The present non-interventional observational study in the Greek population aims at collecting the characteristics of COPD patients selected to be given the inhaled combination of fluticasone propionate and salmeterol in doses of…
- Conditions
- Chronic Obstructive Pulmonary Disease, Compliance, Patient, Quality of Life
- Trial name
- AHEAD (NCT03299673)
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease.
- Trial name
- NCT00453479
- Testing
- GSK233705B
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled, parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03810183
- Testing
- QAW039
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Chronic Obstructive Pulmonary Disease Moderate
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic…
- Trial name
- NCT03028142
- Testing
- 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium
- Volunteers
- 30 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01694771
- Testing
- Tiotropium, Olodaterol
- Where
- 90 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
The study is intended to assess the relative bioavailability of 2 different abediterol nebulised formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04199598
- Testing
- Abediterol (2.4 μg), Abediterol (4.8 μg), Abediterol (2.5 μg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.